ASH 2025: vídeos e entrevistas

555 vídeos do ASH 2025 publicados por ABHH, ASH, OncLive, Oncology Brothers, Targeted Oncology, VJHemOnc e outros. Atualizado em 20/11/2026.

Ver no OncoTV com filtros

CAR T-cell therapy in multiple myeloma: highlights from ASH 2025VJHemOnc · 30/06/2026 · 13:53 · apoio da indústriaPost-remission therapy in older adults with newly diagnosed AML and when to consider transplantVJHemOnc · 20/05/2026 · 2:44 · apoio da indústriaThe role of FLT3 and IDH inhibitors in newly diagnosed older adults with AML based on ASH guidelinesVJHemOnc · 20/05/2026 · 1:38 · apoio da indústriaExploring genomic insights in acute lymphoblastic leukaemia treatmentecancer · 30/04/2026 · 7:11 · apoio da indústriaIP6K1-driven tumour polyphosphate may contribute to immune checkpoint inhibitor-associated throm...ecancer · 30/04/2026 · 4:23 · apoio da indústriaComplement-bound procoagulant platelets predict thrombosis in antiphospholipid syndromeecancer · 30/04/2026 · 4:32 · apoio da indústriaCOVID-19 IgG antibodies induce endothelial activation, barrier dysfunction, and a prothrombotic ...ecancer · 30/04/2026 · 5:14 · apoio da indústriaRusfertide provides durable control of haematocrit and phlebotomy reduction in polycythemia veraecancer · 30/04/2026 · 4:34 · apoio da indústriaLonger follow-up shows promising PFS + MRD negativity for mosunetuzumab use in untreated high tu...ecancer · 30/04/2026 · 7:27 · apoio da indústriaASH 2025: Highlightsecancer · 30/04/2026 · 11:40 · apoio da indústriaFixed-duration targeted treatment as effective as TKI Inhibitor therapy for CLLecancer · 29/04/2026 · 4:28 · apoio da indústriaEpcoritamab plus rituximab and lenalidomide improves efficacy in relapsed or refractory follicul...ecancer · 29/04/2026 · 10:07 · apoio da indústriaRecent BTK inhibitor trial updates across non-Hodgkin lymphoma subtypesVJHemOnc · 20/02/2026 · 26:10 · apoio da indústriaASH 2025 highlights in AL amyloidosis: risk stratification, bispecific antibodies, CAR-T, & MRDVJHemOnc · 06/02/2026 · 28:50 · apoio da indústriaTop ASH 2025 updates in AML: redefining frontline therapy, menin inhibition, & moreVJHemOnc · 03/02/2026 · 18:18 · apoio da indústriaPhase Ib study of bleximenib plus venetoclax in AML with KMT2A or NPM1 alterationsVJHemOnc · 29/01/2026 · 6:23 · apoio da indústriaOptimal ferritin threshold to diagnose IEC-HS following CAR T-cell therapy in R/R myelomaVJHemOnc · 28/01/2026 · 8:27 · apoio da indústriaThe potential of bispecific T-cell engagers targeting FLT3 in AMLVJHemOnc · 28/01/2026 · 1:28 · apoio da indústriaFRIDA study: iadademstat and gilteritinib in FLT3-mutated R/R AMLVJHemOnc · 27/01/2026 · 1:11 · apoio da indústriaAMPLIFY trial: how prognostic mutations impact outcomes with acalabrutinib-venetoclax in CLLVJHemOnc · 27/01/2026 · 2:48 · apoio da indústriaReal-world ibrutinib plus venetoclax in frontline CLL/SLL: REALITY-WW and REALITY-2 outcomesVJHemOnc · 27/01/2026 · 2:09 · apoio da indústriaValidation of MRD as a surrogate endpoint in AML: ongoing research & updates from HARMONY AllianceVJHemOnc · 27/01/2026 · 1:41 · apoio da indústriaNon-opioid and integrative strategies for pain management during VOC in SCDVJHemOnc · 27/01/2026 · 2:24 · apoio da indústriaTreatment strategies for multiple myeloma progressing after upfront quadruplet therapyVJHemOnc · 27/01/2026 · 2:32 · apoio da indústriaMRD as a surrogate endpoint in NPM1-mutated AML: implications for clinical trials and regulationVJHemOnc · 27/01/2026 · 1:15 · apoio da indústriaFollicular Lymphoma Foundation: research mission, biomarkers, and global collaborationVJHemOnc · 27/01/2026 · 2:07 · apoio da indústriaRedefining high-risk myeloma in the context of upfront quadruplet therapy and ASCTVJHemOnc · 27/01/2026 · 3:58 · apoio da indústriaMRD trajectory and prognosis in t(11;14) multiple myeloma treated with quadruplet therapy and ASCTVJHemOnc · 27/01/2026 · 4:19 · apoio da indústriaASH News TV 2025: Welcome to #ASH25ASH · 26/01/2026 · 5:47Real-world barriers to treatment access in T-cell lymphomaVJHemOnc · 26/01/2026 · 3:02 · apoio da indústriaDrivers of racial and ethnic disparities in access to frontline CLL therapy in the USVJHemOnc · 26/01/2026 · 4:03 · apoio da indústriaVMP ± Dara versus Rd ± Dara in transplant-ineligible patients with myeloma: a Phase IV trialVJHemOnc · 26/01/2026 · 2:57 · apoio da indústriaGOLSEEK-1 trial: golcadomide plus R-CHOP in frontline high-risk large B-cell lymphomaVJHemOnc · 26/01/2026 · 1:02 · apoio da indústriaGeriatric assessment-guided treatment in older AML: cognitive and functional predictorsVJHemOnc · 26/01/2026 · 3:38 · apoio da indústriaCXCL10-CXCR3 signaling as a pro-survival pathway and prognostic biomarker in CNS lymphomaVJHemOnc · 26/01/2026 · 4:37 · apoio da indústriaEarly recognition and diagnosis of BPDCN: skin biopsy, markers, and specialist referralVJHemOnc · 26/01/2026 · 1:04 · apoio da indústriaThe prognostic value of ctDNA-based MRD testing in lymphomaVJHemOnc · 26/01/2026 · 1:49 · apoio da indústriaIncorporating novel agents in frontline & relapsed HL: PD-1 inhibitors, brentuximab, and sequencingVJHemOnc · 26/01/2026 · 2:37 · apoio da indústriaVIBER-M: venetoclax, iberdomide, & dexamethasone for multiple myeloma with t(11;14) in early relapseVJHemOnc · 26/01/2026 · 4:58 · apoio da indústriaPatient-informed CRISPR screening reveals gene targets to improve CAR T-cell efficacyVJHemOnc · 26/01/2026 · 1:37 · apoio da indústriaA Phase I study evaluating BAFF ligand-directed CAR T-cells with obinutuzumab in R/R CLL/SLLVJHemOnc · 26/01/2026 · 1:24 · apoio da indústriaVenetoclax enhances T-cell fitness and CAR T-cell manufacturing potential in CLLVJHemOnc · 26/01/2026 · 2:09 · apoio da indústriaLife-years and quality-adjusted outcomes with belantamab mafodotin in RRMM: DREAMM-7 analysisVJHemOnc · 26/01/2026 · 1:55 · apoio da indústriaCD70-targeted CAR T-cells for high-risk myeloma after BCMA CAR-T relapseVJHemOnc · 26/01/2026 · 2:19 · apoio da indústriaImproving CAR T-cell efficacy in myeloma: CRISPR engineering and dual-antigen targetingVJHemOnc · 26/01/2026 · 2:07 · apoio da indústriaConsideration of genomic determinants improves the diagnostic accuracy of oligomonocytic CMMLVJHemOnc · 23/01/2026 · 1:35 · apoio da indústriaALPHA3 study: first-line cema-cel consolidation for MRD-positive LBCL after standard therapyVJHemOnc · 23/01/2026 · 3:41 · apoio da indústriaRuxolitinib plus CDK4/6 inhibitor abemaciclib in previously treated myelofibrosis: Phase I resultsVJHemOnc · 23/01/2026 · 3:26 · apoio da indústriaMorningSun: subcutaneous mosunetuzumab in patients with previously untreated HTB follicular lymphomaVJHemOnc · 23/01/2026 · 7:31 · apoio da indústriaThe role and future of BCL2 inhibitors in HR-MDSVJHemOnc · 23/01/2026 · 2:06 · apoio da indústriaCARDINAL: Phase I study of TERN-701, an allosteric BCR-ABL1 inhibitor, in previously treated CMLVJHemOnc · 23/01/2026 · 2:19 · apoio da indústriaImproving equity in pain management for SCDVJHemOnc · 23/01/2026 · 2:12 · apoio da indústriaASH datasets that will impact clinical practice in 2026: the MajesTEC-3 trial in RRMMVJHemOnc · 23/01/2026 · 1:18 · apoio da indústriaThe potential to "reset" disease progression in MPNs through genome editingVJHemOnc · 23/01/2026 · 1:11 · apoio da indústriaStrategies to further deepen responses to menin inhibitors in AMLVJHemOnc · 23/01/2026 · 1:43 · apoio da indústriaIntronic DNA variants in EZH2 and GATA2 may predict TFR in CMLVJHemOnc · 23/01/2026 · 2:07 · apoio da indústriaCombination regimens to address resistance to menin inhibitors in AMLVJHemOnc · 23/01/2026 · 1:31 · apoio da indústriaComparing haploidentical donors with mismatched unrelated donors in secondary AMLVJHemOnc · 23/01/2026 · 1:22 · apoio da indústriaProspective predictors of toxicity to BCMA‑directed CAR T-cell therapy in multiple myelomaVJHemOnc · 23/01/2026 · 5:01 · apoio da indústriaMutation profiling in patients with secondary compared with de novo AML: a ALWP/EBMT studyVJHemOnc · 23/01/2026 · 1:42 · apoio da indústria